论文部分内容阅读
目的：：探讨分析雷珠单抗在治疗新生血管性青光眼中应用的疗效。方法：选取本院2013年11月-2014年10月间收治的12例(12眼）新生血管性青光眼患者,其中糖尿病视网膜病变的7例,视网膜中央静脉阻塞的4例,1例眼部缺血综合征。均给予雷珠单抗治疗(玻璃体腔注射）,配合全视网膜光凝及手术治疗,术后随访3-6个月,观察比较治疗后虹膜新生血管的消退情况,治疗前及治疗后视力、眼压。结果：玻璃体腔注射雷珠单抗治疗后虹膜新生血管在3-5天内完全消退、萎缩,未出现并发症,9例在一周后行全视网膜光凝术治疗后,其中6例眼压控制良好,2例后行复合小梁外滤过手术,1例行睫状体巩膜外光凝术；未一周后激光的3例在一周后2例行玻璃体切割手术治疗(积血）,术中全视网膜光凝,一例行超声乳化白内障手术,拟行全视网膜光凝,但此例患者未随诊,3个月后再发新生血管青光眼。结论：雷珠单抗治疗新生血管性青光眼,配合全视网膜光凝及手术治疗,效果显著。“,”To investigate the efficacy of ranibizumab analysis in the treatment of neovascular glaucoma applications.[Methods]Select the hospital between November 2013 -2014 October 12 treated patients (12) in patients with neovascular glaucoma, including seven cases of diabetic retinopathy, central retinal vein occlusion in 4 cases, and one case of ocular ischemia comprehensive sign. Were treated with ranibizumab treatment (intravitreal injection), with panretinal photocoagulation and surgical treatment, patients were folowed up for 3-6 months, iris neovascularization subsided after treatment were compared before and after treatment visual acuity, eye press.[Results] lntravitreal ranibizumab therapy iris neovascularization completely subsided within 3-5 days, atrophy, no complications, nine cases in one week underwent panretinal photocoagulation treatment, including six cases of intraocular pressure is wel controled, 2 patients underwent complex outside trabecular filtration surgery, a routine scleral photocoagulation of the ciliary body; not a week after the laser three cases in one week after two routine vitrectomy (blood clots), intraoperative panretinal light condensate, a routine phacoemulsification cataract surgery, scheduled for panretinal photocoagulation, but the patients did not folow up, three months later sent neovascular glaucoma.[Conclusion]Ranibizumab treatment of neovascular glaucoma, with panretinal photocoagulation and surgical treatment, the effect is significant.